HopeStage
Back to all studies
CompletedNCT03128021

Antidepressants and Brain Changes in Older Adults With Depression

About this titleRead the official source — NCT03128021
Medication studyAges 60+United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 60 years.

Listed locations
PittsburghSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 24, 2017
Recruitment status
Completed
Enrollment listed in the registry
57
Sponsor
Howard Aizenstein
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
Over 60 Years
Official registry ID
NCT03128021
Official title
Show the full official title

Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Pittsburgh

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Howard Aizenstein.

Did this study involve medication?

Yes. The study involved medication, including Escitalopram Pill and Levomilnacipran Pill.

Who was this study for?

Listed age limits: from 60 years.

Want to explore more studies?

Explore studies